Business Insider7h
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
77-year-old patient with squamous NSCLC who had previously received carboplatin plus ... We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients ...
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...
manilatimes4d
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
WILMINGTON, Del., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage ...
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...
Nuvation Bio reports Q3 EPS (15c, consensus (13c)
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio (NUVB), reflected on the quarter and stated: “In the ...
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...
manilatimes6d
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Cash Position: Black Diamond ended the third quarter of 2024 with approximately $112.7 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023. Net cash ...